Italian Sunshine Reporting: Why It Gets Left Out of Pharma Digital Transformations
Author
May Khan leads the Compliance Services team at Vector Health, a SaaS company focused on life sciences compliance. Her experience includes global transparency reporting, Sunshine Act strategy, and HCP risk monitoring. At Vector, she coordinates cross-functional teams focused on data integrity, customer service, and regulatory alignment.
Vector Health Compliance
Your Leading Partner in Global Sunshine Compliance
A recent conversation with a senior compliance leader at one of Italy’s top-five consumer care and OTC companies revealed a striking pattern. After months of planning, a dedicated IT consulting firm, brought in specifically to map the Oracle migration, had produced a full gap analysis without a single mention of the Italian Sunshine Act. It was only when the company’s internal compliance champion raised the alarm that transparency obligations were added to the agenda.
This is not an isolated case. Across Italy’s life science sector, Italian transparency reporting tends to fall into a grey zone: too technical for the business side, too regulatory for the IT team, and too specific for generalist consultants. The result? Companies reach the final stages of a digital transformation project, often with a hard deadline, and suddenly discover they have no plan for how their new system will generate, validate, or submit the required data to Sanità Trasparente.
What Is the Italian Sunshine Act?
The Italian Sunshine Act (Law No. 62/2022) establishes Italy’s transparency reporting framework and requires pharmaceutical and medical device companies to publicly disclose transfers of value made to healthcare professionals (HCPs) and healthcare organisations (HCOs). This data must be submitted twice yearly to Sanità Trasparente once the platform is live, which is the portal managed by the Italian Ministry of Health, in a specific XML submission format.
Unlike voluntary European codes, this is a legal obligation. Non-compliant companies risk enforcement action, reputational exposure, and, as the platform matures, increased scrutiny from the Ministry of Health.
For companies undergoing digital transformation, the risk is compounded: architectural decisions made today will determine whether the new system can produce compliant reports of transfers of value related to HCP or HCO interactions at all.
The Cost of Leaving Italian Sunshine Reporting Out of the Blueprint
When Italian Sunshine Reporting is treated as an afterthought, the consequences compound quickly. The consulting team responsible for the Oracle or SAP implementation, focused on delivering a platform blueprint, faces unexpected scope expansion. Internal teams are pulled into emergency meetings. And the compliance officer is left trying to explain XML submission requirements to engineers who have never heard of Sanità Trasparente.
In the case described above, the Oracle migration is slated for go-live in 2027. That seems like plenty of time, until you realise that the architecture decisions being made today will determine whether the system can produce compliant transparency reports at all. Retrofitting Italian Sunshine Act requirements into a fully built Oracle environment is far more expensive and disruptive than designing for them from the start.
The pressure is real because the Ministry of Health has begun preparing the Sanità Trasparente platform for implementation and technical readiness activities. While full compliance timelines continue to evolve, companies that delay building their reporting infrastructure are not simply deferring a task, they are allowing a growing gap to form between their data architecture and their regulatory obligations.
What Good Italian Transparency Reporting Architecture Looks Like
The companies navigating this well share a common approach: they treat Italian transparency reporting not as a reporting task, but as a data architecture requirement. This means defining, early in the transformation project, how data related to HCP and HCO interactions will be captured, where it will be stored, how errors will be flagged and corrected, and what the XML submission workflow will look like.
Crucially, this does not mean companies need to overhaul their existing systems. The right life science compliance partner maps incoming data from whatever source systems are in place, SAP, Oracle, CRM, event management tools, into a single standardized database aligned to the Italian Sunshine Act requirements. The company keeps its infrastructure; the compliance layer sits on top.
This distinction matters enormously. Every pharma company currently exploring Italian Sunshine Reporting solutions has already been in contact with at least one alternative provider. The ability to integrate without disruption, without forcing a system change, is consistently the deciding factor.
A recent conversation with a senior compliance leader at one of Italy’s top-five consumer care and OTC companies revealed a striking pattern. After months of planning, a dedicated IT consulting firm, brought in specifically to map the Oracle migration, had produced a full gap analysis without a single mention of the Italian Sunshine Act. It was only when the company’s internal compliance champion raised the alarm that transparency obligations were added to the agenda.
This is not an isolated case. Across Italy’s life science sector, Italian transparency reporting tends to fall into a grey zone: too technical for the business side, too regulatory for the IT team, and too specific for generalist consultants. The result? Companies reach the final stages of a digital transformation project, often with a hard deadline, and suddenly discover they have no plan for how their new system will generate, validate, or submit the required data to Sanità Trasparente.
What Is the Italian Sunshine Act?
The Italian Sunshine Act (Law No. 62/2022) establishes Italy’s transparency reporting framework and requires pharmaceutical and medical device companies to publicly disclose transfers of value made to healthcare professionals (HCPs) and healthcare organisations (HCOs). This data must be submitted twice yearly to Sanità Trasparente once the platform is live, which is the portal managed by the Italian Ministry of Health, in a specific XML submission format.
Unlike voluntary European codes, this is a legal obligation. Non-compliant companies risk enforcement action, reputational exposure, and, as the platform matures, increased scrutiny from the Ministry of Health.
For companies undergoing digital transformation, the risk is compounded: architectural decisions made today will determine whether the new system can produce compliant reports of transfers of value related to HCP or HCO interactions at all.
The Cost of Leaving Italian Sunshine Reporting Out of the Blueprint
When Italian Sunshine Reporting is treated as an afterthought, the consequences compound quickly. The consulting team responsible for the Oracle or SAP implementation, focused on delivering a platform blueprint, faces unexpected scope expansion. Internal teams are pulled into emergency meetings. And the compliance officer is left trying to explain XML submission requirements to engineers who have never heard of Sanità Trasparente.
In the case described above, the Oracle migration is slated for go-live in 2027. That seems like plenty of time, until you realise that the architecture decisions being made today will determine whether the system can produce compliant transparency reports at all. Retrofitting Italian Sunshine Act requirements into a fully built Oracle environment is far more expensive and disruptive than designing for them from the start.
The pressure is real because the Ministry of Health has begun preparing the Sanità Trasparente platform for implementation and technical readiness activities. While full compliance timelines continue to evolve, companies that delay building their reporting infrastructure are not simply deferring a task, they are allowing a growing gap to form between their data architecture and their regulatory obligations.
What Good Italian Transparency Reporting Architecture Looks Like
The companies navigating this well share a common approach: they treat Italian transparency reporting not as a reporting task, but as a data architecture requirement. This means defining, early in the transformation project, how data related to HCP and HCO interactions will be captured, where it will be stored, how errors will be flagged and corrected, and what the XML submission workflow will look like.
Crucially, this does not mean companies need to overhaul their existing systems. The right life science compliance partner maps incoming data from whatever source systems are in place, SAP, Oracle, CRM, event management tools, into a single standardized database aligned to the Italian Sunshine Act requirements. The company keeps its infrastructure; the compliance layer sits on top.
This distinction matters enormously. Every pharma company currently exploring Italian Sunshine Reporting solutions has already been in contact with at least one alternative provider. The ability to integrate without disruption, without forcing a system change, is consistently the deciding factor.
Author
May Khan leads the Compliance Services team at Vector Health, a SaaS company focused on life sciences compliance. Her experience includes global transparency reporting, Sunshine Act strategy, and HCP risk monitoring. At Vector, she coordinates cross-functional teams focused on data integrity, customer service, and regulatory alignment.
Vector Health Compliance
Your Leading Partner in Global Sunshine Compliance